Advanced Search

 

Study ID Status Title Patient Level Data
CNA30027 & CNA30032 Completed A retrospective, case-control study to investigate genetic polymorphisms in HIV infected subjects who developed hypersensitivity following treatment with abacavir
CNA30027, CNA30032, CNA30021, CNA30024, EPV40001 Completed Final report from the analysis of candidate gene markers and genome-wide single nucleotide polymorphisms(SNPs) from two retrospective, case-control studies and three controlled clinical studies to investigate geneticpolymorphisms in HIV infected subjects who developed hypersensitivity following ...
CNAA1001 Completed A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of 1592U89 in HIV-Infected Children
CNAA3005 Completed A Phase III Randomised, Double-Blind, Multi-center Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Nave Subjects: 48 Week Report
CNAA3006 Completed A Double-Blind, Randomized, Multi-Center Trial to Evaluate the Safety and Efficacy of the Combination of 1592U89/Zidovudine (ZDV)/Lamivudine (3TC) Versus the Combination of Zidovudine (ZDV)/Lamivudine (3TC) in HIV-1 Therapy-Experienced Pediatric Patients
CNAA3007 Completed 1592U89 Open Label Protocol for Pediatric Patients with HIV-1 Infection
CNAA3008 Completed A 1592U89 Open Label Protocol for Adult Patients with HIV-1 Infection
CNAB1006 Completed A study to compare the pharmacokinetics of, and tolerability to, a single, oral, 600mg dose of 1592U89 in HIV positive subjects with and without liver disease.
CNAB2006 Completed A Phase II Open-Label Observational Study of Changes in Immune Function and Lymph Node Architecture During Long-Term Suppression of Viraemia Associated With Early Combination Therapy With Abacavir and Amprenavir in Antiretroviral-Naive HIV-1 Infected Subjects With a CD4+ Cell Count ?400 cells/mm3
CNAB3001 Completed A Phase III, Randomised, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 (Abacavir) in HIV-1 Infected Patients with AIDS Dementia Complex
CNAB3002 Completed A Randomised, Double-blind, Comparative, Parallel-group, Multicentre Trial to Evaluate the Safety and Efficacy of ABC Versus Placebo in Combination with Background Antiretroviral Therapy in HIV-1 Infected Antiretroviral Therapy Experienced Subjects with CD4+ cell counts ? 100 cells/mm³ and Plasm ...
CNAB3003 Completed A Randomized, Double-Blind, Parallel-Group, Multicenter Trial to Evaluate the Safety and Efficacy of 1592U89 in Combination with Lamivudine (3TC) and Zidovudine (ZDV) versus 3TC/ZDV in HIV-1 Infected Antiretroviral Therapy Naive Subjects with CD4+ cell counts ?100 cells/mm³
CNAB3004 Completed An Open-Label Phase III Study to Allow Continued Access to Abacavir for HIV-Infected Adults who Have Completed a Clinical Study From the GlaxoSmithKline International Development Programme for Abacavir (CNAB3004)
CNAB3014 Completed A Phase IIIb Randomised, Open-Label, Multi-centre Study to Evaluate the Safety and Efficacy of ABC/3TC/ZDV Versus IDV/3TC/ZDV in HIV-1 Infected Antiretroviral Therapy Naïve Subjects: 48 Week Report
CNAF3016 Completed A Pilot Study to assess the Efficacy and Safety of a quadritherapy with Combivir, Abacavir, Nelfinavir switching from week 16 to (TZV), Nelfinavir for Antiretroviral Therapy in HIV-infected Naive Subjects with a viral load > 50 000 copies/mL
CNAF3021 Completed Long term follow-up of 2 triple combinations CombivirTM + Ziagen™ and Combivir™ + Viracept™ started in HIV-1 infected antiretroviral therapy naïve subjects within 2 years in study CNAF3007-Ecureuil.
COD10001 Completed A pilot open-labeled, randomized, parallel cohort, pharmacokinetic and pharmacodynamic, multicenter trial of zidovudine (RETROVIR) 600 mg once daily compared to zidovudine 300 mg BID monotherapy for 14 days in HIV infected, therapy naïve patients.
COD20002 Completed A Phase II, Open-Label, Multicenter, Randomized, Parallel Group, 14 Day Pilot Study of Monotherapy with Zidovudine 600mg Once Daily Compared to Zidovudine 300mg Twice Daily in HIV-Infected, Antiretroviral-Naïve Subjects.
COL30267 Completed Initial title: Evaluation of efficacy and safety of combination of Combivir TM(AZT/3TC) and abacavir, in HIV-infected patients with an abacavir-susceptible phenotype and who had received Zerit ® (d4T) and Videx ® (ddl) as first-line treatment with or without non nucleosidic…
COL30281 Completed An open label, randomised study, to evaluate the safety and efficacy of Combivir plus abacavir (Ziagen) versus Combivir plus Viracept, in HIV-1 infected antiretroviral therapy naive adults with a plasma HIV-1 RNA between 1000 and 500,000 copies /mL.
COL30305 Completed A Phase IV, Randomized, Open-Label, Multi-center, Twenty-Four-Week Pilot Study to Evaluate the Efficacy and Safety of Continued Therapy with Two Nucleoside Reverse Transcriptase Inhibitors…
COL30330 Completed A Phase I, 13-Day, Controlled, Open-Label Pharmacokinetic Evaluation of Methadone Following Co-Administration with Amprenavir in Opiate-Dependent Subjects
COL30336 Completed A Phase IV, Open-Label, Multicenter Study of the Efficacy and Safety of Quadruple Combination Antiretroviral Therapy with COMBIVIR (Lamivudine 150mg/Zidovudine 300mg) BID, ZIAGEN (Abacavir) 300mg BID, and SUSTIVA (Efavirenz) 600mg QD for 24 Weeks, Followed by Therapy with the Triple Nucleoside C ...
COL30352 Completed A pilot study to evaluate the efficacy and safety of a combination of antiretroviral drugs including amprenavir with or without ritonavir, two or three nucleoside analogs in HIV-1 infected patients who are in virological escape after a first, second or third line therapy including at least one p ...
COL30406 Completed A Study to Investigate the Pharmacokinetic Interaction Between Amprenavir and Ritonavir Following Their Co-Administration in Subjects with HIV-1 infection (PROF1003).

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.